Oncocross Completes Merger with Oncomaster, Issuing 850,397 New Shares Resulting in ~7% Dilution
The merger completion report confirms that Oncocross has officially absorbed Oncomaster.
Oncocross issued 850,397 new shares to Oncomaster shareholders at a merger ratio of 5.2100960 to 1, resulting in approximately 7% dilution of existing shares.
Except for 4 fractional shares, the entire 850,393 new shares are subject to a 1-year escrow, limiting immediate market supply.
As a small-scale merger, no appraisal rights were granted; only 102,605 shares or 0.84% of total outstanding shares opposed the merger.
No creditors filed objections during the objection period, and no litigation related to the merger is pending.
Post-merger balance sheet shows total assets of 30.2 billion KRW, total liabilities of 17.5 billion KRW, and total equity of 12.7 billion KRW, with accumulated deficit increasing to 61.1 billion KRW.
[AI Summary]Oncocross's merger with Oncomaster causes approximately 7% dilution, but the 1-year escrow on all new shares limits short-term overhang. The financial impact is neutral as equity slightly decreased due to higher liabilities, with no immediate value enhancement. Given the smooth closure and escrow conditions, the stock price impact is expected to be neutral.